STOCKS TELEGRAPH

Tag: Inovio Pharmaceuticals Inc.

  • 35 stocks making the biggest moves premarket today

    35 stocks making the biggest moves premarket today

    FuelCell Energy Inc. (FCEL) stock soared 4.75% to $10.15 in the pre-market trading. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.

    SCWorx Corp. (NASDAQ: WORX) shares are trading down -6.76% at $2.07 at the time of writing. Company’s 52-week ranged between $1.00 to $14.88.

    Nano Dimension Ltd. (NNDM) lost over -12.1% at $5.74 in pre-market trading Monday, November 30, 2020, after announcing that it has entered into definitive agreements with investors for the sale of 11,960,160 of the Company’s American Depositary Shares (“ADSs”) at a price of $5.00 per ADS pursuant to a registered direct offering.

    Moderna Inc. (MRNA) is up more than 9.38% at $138.95 in pre-market hours on Monday, November 30, 2020 after the firm today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. The stock had jumped over 16.35% to $127.03 in the last trading session.

    FreightCar America Inc. (NASDAQ: RAIL) shares are trading down -3.99% at $2.65 at the time of writing. Company’s 52-week ranged between $0.73 to $2.87. Analysts have a consensus price target of $4.50.

    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -3.25% at $27.09 in pre-market trading Monday. The firm recently declared that it has acquired the EV charging operator U-Go Stations, Inc. and its portfolio of 44 DCFC charging locations.

    Zomedica Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -1.12% at $0.1324 in pre-market trading Monday.

    GameStop Corp. (GME) is up more than 4.1% at $16.74 in pre-market hours Monday November 30, 2020 after declaring 2020 cyber week deals. The stock had jumped over 9.02% to $16.08 in the last trading session. GameStop Announces 2020 Cyber Week Deals.

    Riot Blockchain Inc. (RIOT) grew over 8.64% at $6.79 in pre-market trading today.

    Verastem Inc. (VSTM) stock moved up 5.03 percent to $2.09 in the pre-market trading after reporting the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC).

    Tuniu Corporation (TOUR) gained over 6.58% at $3.4 in pre-market trading on Monday, November 30, 2020. Before the trading started on November 30, 2020.

    Novavax Inc. (NVAX) is down -8.31% to reach $115.25 after providing an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. It has been trading in a 52-week range of $3.65 to $189.40.

    Occidental Petroleum Corporation (NYSE: OXY) shares are trading down -2.36% at $16.17 at the time of writing. Company’s 52-week ranged between $8.52 to $47.58. Analysts have a consensus price target of $18.

    RMG Acquisition Corp. (RMG) stock soared 6.6% to $18.1 in the pre-market trading. The firm recently revealed that the close of business on Tuesday, December 1, 2020, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the special meeting to be held to consider and approve the previously announced merger with Romeo Systems, Inc., a Delaware corporation.

    Uxin Limited (UXIN) stock soared 2.53% to $1.62 in the pre-market trading. The most recent rating by JP Morgan, on October 23, 2019, is a Neutral.

    ReneSola Ltd (NYSE: SOL) shares are trading up 8.02% at $8.08 at the time of writing. The technology company recently announced the closing of the sale of a portfolio of operating projects located in the United Kingdom to Atmosclear Investments Ltd, an European renewable energy and cleantech private equity group. Company’s 52-week ranged between $0.85 to $5.67. Analysts have a consensus price target of $22.

    Kandi Technologies Group Inc. (KNDI) tumbled over -2.28% at $13.31 in pre-market trading today after CBAK Energy and Kandi Group signed a supply framework agreement.

    Vaxart Inc. (VXRT) is up more than 4.84% at $7.37 in pre-market hours on Monday, November 30, 2020. The stock had jumped over 9.84% to $7.03 in the last trading session. Before the trading started on November 30, 2020.

    Alibaba Group Holding Limited (BABA) is down -2.3% to reach $270.13. The internet retail company has been named a leader in Gartner’s 2020 Magic Quadrant for Cloud Database Management Systems. It has been trading in a 52-week range of $169.95 to $319.32.

    EyePoint Pharmaceuticals Inc. (EYPT) stock soared 1.97% to $0.55 in the pre-market trading. The most recent rating by B. Riley FBR, on April 06, 2020, is a Neutral.

    Canaan Inc. (NASDAQ: CAN) shares are trading down -7.83% at $5.3 at the time of writing after releasing its unaudited financial results for the three months ended September 30, 2020. Company’s 52-week ranged between $1.76 to $8.69.

    Heat Biologics Inc. (NASDAQ: HTBX) shares are trading down -0.88% at $1.13 at the time of writing. Company’s 52-week ranged between $0.19 to $4.30. Analysts have a consensus price target of $4.

    Yunji Inc. (YJ), an Internet Retail company, dropped about -7.35% at $3.53 in pre-market trading Monday. The firm recently declared its unaudited financial results for the third quarter ended September 30, 2020.

    India Globalization Capital Inc. (IGC) gained over 22.63% at $2.33 in pre-market trading Monday November 30, 2020.

    Oramed Pharmaceuticals Inc. (ORMP) stock moved up 38.65 percent to $6.17 in the pre-market trading. The healthcare firm recently reported that it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Before the trading started on November 30, 2020.

    Schlumberger Limited (SLB) is down -2.06% to reach $21.43. It has been trading in a 52-week range of $11.87 to $41.14.

    Ocugen Inc. (OCGN) stock plunged -1.71% to $0.294 in the pre-market trading. The firm recently revealed that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. Before the trading started on November 30, 2020.

    Gold Fields Limited (GFI) is down -2.52% to reach $8.5. It has been trading in a 52-week range of $3.79 to $14.90. Before the trading started on November 30, 2020.

    Marathon Patent Group Inc. (MARA) is up 15.65% to reach $4.95. It has been trading in a 52-week range of $0.35 to $6.05.

    Kingsoft Cloud Holdings Limited (KC) stock soared 5.13% to $43.69 in the pre-market trading after reporting that it will be included in the MSCI China Index, effective after the U.S. market close on November 30, 2020. The most recent rating by Goldman, on June 29, 2020, is a Buy.

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading up 5.26% at $0.8 at the time of writing. Company’s 52-week ranged between $0.54 to $3.50.

    Waitr Holdings Inc. (WTRH) stock moved down -1.46 percent to $3.38 in the pre-market trading.

    Hennessy Capital Acquisition Corp. IV (HCAC) gained over 9.0% at $13.69 in pre-market trading on Monday, November 30, 2020.

    Trevena Inc. (TRVN) stock plunged -4.67% to $2.45 in the pre-market trading. The most recent rating by Guggenheim, on September 14, 2020, is a Buy.

    Suncor Energy Inc. (NYSE: SU) shares are trading down -0.58% at $17.15 at the time of writing. The firm lately publicized that it, together with the other Syncrude joint venture owners – Imperial Oil Resources Limited, CNOOC Oil Sands Canada, and Sinopec Oil Sands Partnership – have agreed in principle for Suncor to become the operator of the Syncrude project by the end of 2021. Company’s 52-week ranged between $9.60 to $34.56.

  • 41 Stocks Taking Bigger Strides in Pre-Market Session

    41 Stocks Taking Bigger Strides in Pre-Market Session

    IMAC Holdings Inc. (IMAC) stock plunged -13.16% to $1.32 in the pre-market trading after the company reported third-quarter earnings. The most recent rating by Ascendiant Capital Markets, on April 15, 2020, is at a Buy.

    Allied Healthcare Products Inc. (NASDAQ: AHPI) shares are trading down -10.31% at $7.05 at the time of writing. The company’s 52-week range was noted as $0.92 to $45.00.

    EuroDry Ltd. (EDRY) tumbled over -16.9% at $5.9 in pre-market trading today following Company posted results for the nine-month period and quarter ending September 30, 2020.

    Pyxis Tankers Inc. (PXS), a Marine Shipping company, dropped about -11.86% at $1.04 in pre-market trading Friday as a result of publication stating announcement date of quarterly results and conferencing call.

    XPeng Inc. (XPEV) stock moved up 5.41 percent to $47.15 in the pre-market trading after the news that it has posted strong operating and financial results as a public company.

    Electra Meccanica Vehicles Corp. (SOLO) gained over 18.01% at $5.7 in pre-market trading Friday 13 November 2020 as the company posted robust 3rd quarter results.

    Li Auto Inc. (LI) is up more than 19.57% at $38.0 in pre-market hours Friday 13 November 2020 as the news appeared that the company has announced unaudited Q3 earnings. The stock had jumped over 27.27% to $31.78 in the last trading session.

    Before the trading started on 13 November 2020, Sino-Global Shipping America Ltd. (SINO) is down -7.02% to reach $2.25 following the company revealed earnings scores of fiscal 2020. It has been trading in a 52-week range of $1.37 to $4.89.

    Biocept Inc. (BIOC) stock plunged -15.42% to $5.21 in the pre-market trading as the firm posted third-quarter earnings. The most recent rating by Chardan Capital Markets, on November 14, 2017, is at a Buy.

    Fulgent Genetics Inc. (NASDAQ: FLGT) shares are trading up 6.63% at $41.0 at the time of writing after the news surfaced that company has reported record 3rd quarter earnings and raised its outlook for full-year 2020. The company’s 52-week range was noted as $6.70 to $52.47. Analysts have a consensus price target of $75.

    Zhongchao Inc. (ZCMD) tumbled over -10.7% at $1.92 in pre-market trading today after it was publicized that Zhongchao Inc. and Takeda pharmaceutical will expand the extent of collaboration in China.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, rose about 28.46% at $5.1 in pre-market trading.

    Aeterna Zentaris Inc. (AEZS) lost over -11.11% at $0.32 in pre-market trading Friday 13 November 2020 as it was reported that the giant has announced its 3rd quarter earnings results as well provided business update.

    Northern Dynasty Minerals Ltd. (NAK) is down more than -4.5% at $0.885 in pre-market hours Friday 13 November 2020. The stock had jumped over 13.08% to $0.93 in the last trading session.

    Before the trading started on 13 November 2020, 9F Inc. (JFU) is down -9.68% to reach $1.12. It has been trading in a 52-week range of $0.72 to $11.41.

    Boxlight Corporation (BOXL) stock soared 4.97% to $1.69 in the pre-market trading after the news that the company is set to hold data for its Q3 earnings results and conference call. The most recent rating by National Securities, on May 19, 2020, is at a Buy.

    CureVac N.V. (NASDAQ: CVAC) shares are trading up 5.83% at $73.75 at the time of writing as cureVac’s COVID-19 vaccine candidate, CVnCoV, is suitable for standard fridge temperature Logistics. The company’s 52-week range was noted as $36.15 to $85.00.

    NIO Limited (NIO) grew over 5.57% at $50.99 in pre-market trading today as the news surfaced that the Chinese maker of electric vehicles, Nio Inc (NASDAQ: NIO), is facing intensified competition from Tesla Inc (NASDAQ: TSLA), which will only get more serious with the introduction of its China-made Model Y car.

    Revlon Inc. (REV), a Household & Personal Products company, dropped about -8.49% at $11.0 in pre-market trading Friday after the reports that company sales dropped during the third fiscal quarter.

    Kandi Technologies Group Inc. (KNDI) stock moved up 12.72 percent to $7.8 in the pre-market trading after it was revealed in the news that Kandi Technologies announced the closing of a registered direct placement of $60 million of common stock and warrants.

    Niu Technologies (NIU) gained over 4.49% at $33.29 in pre-market trading Friday 13 November 2020 as it was reported the company will announce its quarterly results on November 23, 2020.

    Onconova Therapeutics Inc. (ONTX) is down more than -10.86% at $0.2601 in pre-market hours Friday 13 November 2020 as news appeared that the company has issued a business update and reveled its quarterly earnings results. The stock had jumped over 7.99% to $0.29 in the last trading session.

    Before the trading started on 13 November 2020, Futu Holdings Limited (FUTU) is up 4.7% to reach $41.68 as it was publicized that the company’s stock will be added to the MSCI Hong Kong Small Cap Index. It has been trading in a 52-week range of $8.16 to $40.99.

    Fisker Inc. (FSR) stock soared 5.86% to $15.89 in pre-market trading. The most recent rating by Cowen, on November 09, 2020, is at an Outperform.

    Novavax Inc. (NASDAQ: NVAX) shares are trading up 5.43% at $95.8 at the time of writing. The company’s 52-week range was noted as $3.54 to $189.40 after the report that company loss widened in Q3 and revenues missed analysts’ estimates. Analysts have a consensus price target of $290.

    Kaixin Auto Holdings (KXIN) grew over 9.46% at $3.47 in pre-market trading today.

    Vipshop Holdings Limited (VIPS), an Internet Retail company, rose about 6.09% at $23.5 in pre-market trading Friday after the exciting news surfaced that the stock earnings beat analysts’ predictions.

    Inovio Pharmaceuticals Inc. (INO) stock moved up 4.75 percent to $11.9 in the pre-market trading after the company posted its third-quarter results.

    Fastly Inc. (FSLY) gained over 4.94% at $80.01 in pre-market trading Friday 13 November 2020.

    Verastem Inc. (VSTM) is up more than 4.64% at $1.58 in pre-market hours Friday 13 November 2020 after the company highlighted its recent progress along with its quarterly results. The stock had jumped over 5.59% to $1.51 in the last trading session.

    Before the trading started on 13 November 2020, NovaBay Pharmaceuticals Inc. (NBY) is down -19.99% to reach $0.52 as the company posted Q3 earnings reports. It has been trading in a 52-week range of $0.24 to $1.94.

    Digital Ally Inc. (DGLY) stock plunged -7.51% to $2.34 in the pre-market trading after the publication of the company’s Q3 operating results. The most recent rating by Aegis Capital, on June 29, 2020, is at a Buy.

    Jumia Technologies AG (NYSE: JMIA) shares are trading up 5.01% at $14.25 at the time of writing after the company said that it has managed to cut down on losses after making a strategic shift due to covid-19. The company’s 52-week range was noted as $2.15 to $23.90. Analysts have a consensus price target of $4.50.

    JD.com Inc. (JD) grew over 4.83% at $90.55 in pre-market trading today after the company revealed the date of its earnings call.

    Creative Realities Inc. (CREX), a Software – Application company, dropped about -15.53% at $0.87 in pre-market trading Friday as the company reported its third-quarter 2020 results.

    Myovant Sciences Ltd. (MYOV) stock moved up 6.43 percent to $18.22 in the pre-market trading following Corporate Updates and Financial Results for the second-quarter fiscal year 2020.

    Cassava Sciences Inc. (SAVA) lost over -19.59% at $8.99 in pre-market trading Friday 13 November 2020 as Cassava Sciences announced a proposed public offering of common stock.

    Four Seasons Education (Cayman) Inc. (FEDU) is down more than -6.41% at $0.82 in pre-market hours Friday 13 November 2020. The stock had jumped over 2.82% to $0.88 in the last trading session.

    Before the trading started on 13 November 2020, Bionano Genomics Inc. (BNGO) is down -6.65% to reach $0.535 as the company revealed its latest business update along with quarterly earnings results. It has been trading in a 52-week range of $0.25 to $1.39.

    Blink Charging Co. (BLNK) stock plunged -5.94% to $9.82 in the pre-market trading as the company revealed both quarterly and nine-month 2020 results. The most recent rating by H.C. Wainwright, on August 14, 2020, is at a Neutral.

    Farfetch Limited (NYSE: FTCH) shares are trading up 15.71% at $50.0 at the time of writing as the company posted Q3 earnings results. The company’s 52-week range was noted as $5.99 to $44.73. Analysts have a consensus price target of $42.

    Kensington Capital Acquisition Corp. (KCAC) grew over 11.19% at $15.9 in pre-market trading today after the company announced on November 25, 2020, a special meeting will be held to approve the business combination.

    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -2.93% at $0.9998 in pre-market trading Friday following Aytu BioScience announced fiscal Q1 2021 net revenue of $13.5 Million, an increase of 839% year-over-year.

    Palatin Technologies Inc. (PTN) stock moved up 4.22 percent to $0.4151 in the pre-market trading after it reports 1st quarter and fiscal year 2021 results; Teleconference and Webcast to be held on November 17, 2020.

    SPI Energy Co. Ltd. (SPI) gained over 5.43% at $8.15 in pre-market trading Friday 13 November 2020.

    Nabriva Therapeutics plc (NBRV) stock soared 6.41% to $0.45 in the pre-market trading. The most recent rating by Wedbush, on March 19, 2020, is at a Neutral. Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences.

    Timber Pharmaceuticals Inc. (AMEX: TMBR) shares are trading up 5.32% at $0.99 at the time of writing after the announcement of the business update and 3rd quarter results. The company’s 52-week range was noted as $0.87 to $12.60.

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

  • Here’s Why You Should Hold These 15 Biotech Stocks

    Here’s Why You Should Hold These 15 Biotech Stocks

    The biotechnology industry is considered to be an attractive industry for investors as the investors are always looking for safe and secure investments. This industry is a good option for investors as it is a strong and profitable industry. Companies in the biotechnology industry are continuously striving and exploring treatment for rare diseases. This industry has a significant contribution to the well-being of society. The biotechnology industry is constantly experiencing tech improvements and new scientific discoveries.

    Technology has always been at the heart of the biotechnology industry. New technological advancements are helpful for the biotechnology industry. This industry is anticipated to show a higher growth rate over the period of the next seven years. Globally, it is predicted that this industry will generate massive revenue in the coming years and it will also provide investment opportunities to investors who want to invest in the research and development of this industry.

    The following are the leading companies in the biotechnology industry. Let check how these companies are providing the best services to their clients:

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares were trading down -10.49% at $9.30 at the time of writing on Friday. Sorrento Therapeutics Inc. (NASDAQ: SRNE) share price went from a low point around $1.45 to briefly over $19.39 in the past 52 weeks, though shares have since pulled back to $9.30. SRNE market cap has remained high, hitting $2.72B at the time of writing, giving it a price-to-sales ratio of more than 70.

    Sorrento Therapeutics Inc. (SRNE) has announced earlier that it has secured the receipt of clearance from a Brazilian regulatory agency to continue with a Phase 2 clinical trial of Abivertinib in mild, moderate, and severe COVID-19 patients. If we look at the recent analyst rating SRNE, H.C. Wainwright reiterated coverage on SRNE shares with a Buy rating.

    EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT)

    EyePoint Pharmaceuticals Inc. (EYPT) last closed at $0.48, in a 52-week range of $0.46 to $2.69. EyePoint Pharmaceuticals Inc. (EYPT) revealed changes to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the covenant associated with the Company’s net product revenue of DEXYCU and YUTIQ for the twelve-month period ending on December 31, 2020.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (VXRT) stock drop by -3.49% to $6.08. The most recent rating by H.C. Wainwright, on August 12, 2020, is at a Buy. The Schall Law Firm disclosed that the class-action lawsuit has been lodged against Vaxart, Inc. (VXRT)  for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) shares headed falling, lower as much as -4.59%. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral. Novan Inc. (NOVN) revealed earlier that the positive in vitro results exhibited the potential efficacy of its NITRICIL™ platform technology as an antiviral against SARS-CoV-2, the virus that causes COVID-19.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 3.42% after gaining more than $0.13 on Friday. Akebia Therapeutics Inc. (AKBA) revealed that it is scheduled to present data from its global Phase 3 programs of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis ) and not on dialysis at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week) on October 22 – 25, 2020.

    Royalty Pharma plc (NASDAQ: RPRX)

    Royalty Pharma plc (RPRX) last closed at $41.81, in a 52-week range of $38.54 to $56.50. Analysts have a consensus price target of $52.67. Royalty Pharma plc (RPRX) disclosed today that it is scheduled to announce its third-quarter 2020 financial results on Wednesday, November 11, 2020, before the U.S. financial markets open.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceuticals Incorporated (VRTX) stock soar by 1.30% to $218.08. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Vertex Pharmaceuticals Incorporated (VRTX) shared an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) Shares headed falling, lower as much as -1.44%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) earlier revealed it has appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.29, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) earlier disclosed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1×1 meetings scheduled through the Bio Partnering system.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) Shares headed falling, lower as much as -2.17%. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier disclosed the initiation of a rolling submission to Health Canada for mRNA-1273. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults.

    Selecta Biosciences Inc. (NASDAQ: SELB)

    Selecta Biosciences Inc. (NASDAQ: SELB) rose 18.01% after gaining more than $0.38 on Friday. Selecta Biosciences Inc. (SELB) has earlier announced an agreement with IGAN Biosciences, Inc. The agreement is the Research License and Option agreement signed to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).

    Immunomedics Inc. (NASDAQ: IMMU)

    Immunomedics Inc. (NASDAQ: IMMU) stock soar by 0.08% to $87.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics Inc. (IMMU) disclosed that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy orphan status for the treatment of adult and pediatric patients with glioblastoma.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) fall -0.75% after losing more than -$0.05 on Friday. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks. It has moved up 102.56% from its 52-weeks low and moved down -65.83% from its 52-weeks high. CLVS market cap has remained high, hitting $532.72 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock drop by -2.95% to $11.85. The most recent rating by Maxim Group, on September 28, 2020, is at a Buy. Inovio Pharmaceuticals Inc. (INO) share price went from a low point around $2.09 to briefly over $33.79 in the past 52 weeks. It has moved up 456.84% from its 52-weeks low and moved down -65.56% from its 52-weeks high. INO market cap has remained high, hitting $2.05 Billion at the time of writing.

    MannKind Corporation (NASDAQ: MNKD)

    MannKind Corporation (NASDAQ: MNKD) last closed at $2.00, in a 52-week range of $0.80 to $2.48. MannKind Corporation (MNKD) has moved up 157.08% from its 52-weeks low and moved down -17.07% from its 52-weeks high. MNKD market cap has remained high, hitting $441.20 Million at the time of writing.

  • 20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    Investors are always looking for safe and secure investments and as a strong and profitable industry, the biotechnology industry is considered to be an attractive area of investment. This industry has experienced massive growth in recent years and is continuously adopting new technological advancements to keep pace with the fast-growing market. Biotechnology is a set of tools that uses living organisms to create or change a product, improve plants, trees, or animals, or develop microorganisms for specific uses.

    Modern Biotechnology’s main focus is on medicine. The companies in this sector are involved in the development of new treatments for various complex diseases. Technology has always been at the heart of the biotechnology industry. As the new technologies emerged with the passage of time the efficiency of companies has also improved. Similarly, technological advancements have also changed the clinical trial process.

    There are various other trends that the companies are following. Let see the top 20 companies in the biotechnology industry to get a better view:

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $11.47, in a 52-week range of $1.05 to $11.25. Analysts have a consensus price target of $17.00. Cassava Sciences Inc. (SAVA) has earlier announced the results of the Phase 2b study with its drug candidate Sumifilam, in Alzheimer’s disease. The clinical study which has received the funding by the National Institutes of Health (NIH) has shown the improvement in Alzheimer’s disease. Cassava Sciences Inc. (SAVA) market cap has remained high, hitting $242.02 M at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 10.21% to $16.94. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has revealed that the US Food and Drug Administration (FDA) has informed the company that it has some questions related to the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. the company said that it will halt the trial until it clear all the ambiguities of FDA.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) Shares headed rising, higher as much as 4.84%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (SRNE) has earlier revealed the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain at the 14th Annual Pain Therapeutics Summit. The company has reported the encouraging results from its Phase 1b study to evaluate Epidural Resiniferatoxin Injection.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) rose 7.40% after gaining more than $0.51 on Friday. Pomerantz LLP is investigating claims on behalf of investors of Vaxart, Inc. Vaxart Inc. share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.40. Vaxart Inc.’s market cap has remained high, hitting $752.43 M at the time of writing.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) stock soar by 10.86% to $113.56. The most recent rating by H.C. Wainwright, on August 06, 2020, is at a Buy. Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.23%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (ONTX) earlier revealed that it has started the Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals. Onconova has partnered with HanX Biopharmaceuticals in December 2017 for the development, registration, and commercialization of ON 123300 in China.

    Jaguar Health Inc. (NASDAQ: JAGX)

    Jaguar Health Inc. (NASDAQ: JAGX) last closed at $0.31, in a 52-week range of $0.29 to $1.38. Jaguar Health Inc. (JAGX) earlier revealed itis scheduled to participate in its first “Diarrhea Dialogues” virtual event on October 20 from 3:00 PM. The event, open to the financial and business community, will discuss the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy.

    Zogenix Inc. (NASDAQ: ZGNX)

    Zogenix Inc. (NASDAQ: ZGNX) stock drop by -1.46% to $17.50. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. Zogenix Inc. (ZGNX) has revealed the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) Shares headed rising, higher as much as 4.04%. The most recent rating by Guggenheim, on September 14, 2020, is at a Buy. Trevena Inc. (TRVN) has earlier participated in three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting. The meetings have taken place from September 21st to 23rd, 2020.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) last closed at $3.08, in a 52-week range of $0.47 to $6.93. VBI Vaccines Inc. (VBIV) is scheduled to participate in upcoming presentations including Sci-B-Vac: Results on Ph3 Hep B vaccine, Targeting CMV for the development of effective GBM immunotherapy on September 29 and 30, 2020, respectively. It has today participated in the COVID-19 panel discussion on the topic: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

    Brickell Biotech Inc. (NASDAQ: BBI)

    Brickell Biotech Inc. (NASDAQ: BBI) Shares headed rising, higher as much as 3.90%. The most recent rating by Lake Street, on August 28, 2020, is at a Buy. Brickell Biotech Inc. (BBI) has revealed that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. has received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the treatment of primary axillary (underarm) hyperhidrosis.

    VYNE Therapeutics Inc. (NASDAQ: VYNE)

    VYNE Therapeutics Inc. (NASDAQ: VYNE) Shares headed falling, lower as much as -6.17%. VYNE Therapeutics Inc. (VYNE) has revealed that the Company will host a physician symposium on AMZEEQ and ZILXI™ on Thursday, October 1, 2020. VYNE market cap has remained high, hitting $271.70-M at the time of writing.

    Acorda Therapeutics Inc. (NASDAQ: ACOR)

    Acorda Therapeutics Inc. (NASDAQ: ACOR) shares were trading up 30.13% at $0.62 at the time of writing on Friday. Acorda Therapeutics Inc. (NASDAQ: ACOR) share price went from a low point around $0.42 to briefly over $3.27 in the past 52 weeks, though shares have since pulled back to $0.62. ACOR market cap has remained high, hitting $22.70M at the time of writing, giving it a price-to-sales ratio of more than 0. If we look at the recent analyst rating ACOR, H.C. Wainwright downgraded coverage on ACOR shares with a Neutral rating.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) last closed at $69.47, in a 52-week range of $13.53 to $95.21. Analysts have a consensus price target of $91.90. Moderna Inc. (MRNA) has moved up 413.45% from its 52-weeks low and moved down -327.03% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 17.30. This company’s market capitalization has remained high, hitting $25.72 billion at the time of writing.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 7.77% after gaining more than $0.15 on Friday. iBio Inc. (IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.08. iBio Inc. has moved up 4060.00% from its 52-weeks low and moved down -72.08% from its 52-weeks high.  IBIO market cap has remained high, hitting $336.61 M at the time of writing.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 0.81% after gaining more than $0.02 on Friday.  In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.34 and a high of $13.71. It has moved up 5.98% from its 52-weeks low and moved down -8191% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 2.30. This company’s market capitalization has remained high, hitting $347.50 million at the time of writing.

    Vaccinex Inc. (NASDAQ: VCNX)

    Vaccinex Inc. (NASDAQ: VCNX) stock drop by -1.10% to $1.79. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral. Vaccinex Inc. (VCNX) share price went from a low point around $1.70 to briefly over $12.23 in the past 52 weeks, though shares have since pulled back to $1.79. VCNX has moved up 5.29% from its 52-weeks low and moved down -85.36% from its 52-weeks high.  VCNX market cap has remained high, hitting $36.19M at the time of writing.

    Ocugen Inc. (NASDAQ: OCGN)

    Ocugen Inc. (NASDAQ: OCGN) rose 2.29% after gaining more than $0.0 on Friday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.17 and a high of $16.80. It has moved up 78.53% from its 52-weeks low and moved down -98.19% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 3.30. This company’s market capitalization has remained high, hitting $40.03 million at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NMTR) last closed at $0.76, in a 52-week range of $0.37 to $1.22. 9 Meters Biopharma Inc. (NMTR) has moved up 106.59% from its 52-weeks low and moved down -37.33% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.30. This company’s market capitalization has remained high, hitting $101.25 million at the time of writing.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock soar by 3.25% to $5.88. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks, though shares have since pulled back to $5.88. CLVS has moved up 100.68% from its 52-weeks low and moved down -66.15% from its 52-weeks high.  CLVS market cap has remained high, hitting $502.33M at the time of writing.

     

  • Should You Invest In Inovio Pharmaceuticals (NASDAQ: INO)?

    Should You Invest In Inovio Pharmaceuticals (NASDAQ: INO)?

    Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company has recorded an increase of 35.88% in its shares price as it has gained +4.89 on Wednesday. Inovio Pharmaceuticals has earlier participated in H.C. Wainwright 22nd Annual Global Investment Conference on September 14 where its CEO J. Joseph Kim has made two statements that excited its investors.

    CEO J. Joseph disclosed that the Phase 1 study of its coronavirus vaccine candidate INO-4800 is currently in the peer review. He also revealed that the Inovio will soon announce the result of peer review in the coming weeks. Secondly, Inovio’s CEO said that the company is planning to start phase 2/3 testing for its investigational vaccine. The biotech company is waiting for the FDA approval for phase 2/3 which the company expects will happen soon. Inovio said that it is confident that it will receive the funding for the upcoming trials of the vaccine.

    Inovio Pharmaceuticals is scheduled to participate in the upcoming two conferences including Cantor Global Healthcare Conference on September 17 and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit which will take place on September 23. Investors expected that the biotechnology company will announce the exciting news soon.

    Inovio Pharmaceuticals (NASDAQ: INO) shares were trading up 35.88% at $18.52 at the time of writing on Thursday.  INO share price went from a low point around $1.91 to briefly over $33.79 in the past 52 weeks. It has moved up 867.10% from its 52-weeks low and moved down -45.19% from its 52-weeks low. If we look at its liquidity, it has a current ratio of 10.10. Inovio market cap has remained high, hitting $2.99 billion at the time of writing.

    The company has earlier shared the result from the Phase 1 clinical trial of the coronavirus vaccine candidate but the industry investors were not satisfied with the result as the company didn’t give any details about immune responses in patients. But it is expected that the upcoming peer review could clear the doubts of industry observers.

    Shares of Inovio Pharmaceuticals has experienced an unusual options activity on Wednesday trading session. The large volume is one option activity that is considered to be unusual. The volume of options activity means the number of shares contracts traded for a day. INO has experienced bullish sentiments which means to buy at/near ask price or a put is sold at/near bid price.

    Previously, Inovio Pharmaceuticals has signed a contract with Thermo Fisher Scientific for the development of a coronavirus vaccine candidate, INO-4800. Inovio is planning to make the 100 million doses of INO-4800 by 2021 after receiving FDA approval.

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.